Is Nolvadex affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2D6

Nolvadex is affected by pharmacogenetics through the CYP2D6 gene. Your genotype for this gene can change how your body processes Nolvadex, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Nolvadex

tamoxifen affected by CYP2D6

Affected by CYP2D6 · CPIC · Strong evidence

Read the full tamoxifen genetics guide →

Tamoxifen phenotype recommendations

Published guidance from CPIC on how tamoxifen should be dosed or substituted based on your CYP2D6 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2D6	Your body converts tamoxifen into its active form effectively. The standard dose should provide the intended benefit for breast cancer treatment.	CPIC Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Strong
Normal Metabolizer CYP2D6	Your body converts tamoxifen into its active form at a normal rate. The standard dose should provide the intended benefit for breast cancer treatment.	CPIC Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Strong
Intermediate Metabolizer CYP2D6	Your body converts tamoxifen into its active form less effectively than normal, which may reduce the drug's ability to prevent breast cancer recurrence. An alternative hormonal therapy or a higher dose may be considered.	CPIC Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.	Moderate
Poor Metabolizer CYP2D6	Your body has difficulty converting tamoxifen into its active form, which significantly reduces the drug's ability to prevent breast cancer recurrence. An alternative hormonal therapy is strongly recommended.	CPIC Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy.	Strong
Indeterminate CYP2D6	The impact of your genotype on response to this drug is unknown	CPIC Initiate therapy with recommended starting dose.	—
Not available CYP2D6	The impact of your genotype on response to this drug is unknown	CPIC Initiate therapy with recommended starting dose.	—

Source: CPIC

The gene behind the guidance

CYP2D6 Cytochrome P450 2D6

CYP2D6 is the most clinically important pharmacogene. It metabolizes around a quarter of all prescription drugs, including many antidepressants, opioids, and stimulants. The gene is unusually variable: roughly 7 percent of people are poor metabolizers (they barely activate CYP2D6), and another 1 to 3 percent are ultrarapid metabolizers (their enzyme is overactive).

For most CYP2D6 drugs, poor metabolizers feel stronger effects and more side effects at standard doses, while ultrarapid metabolizers may feel almost nothing. For prodrugs like codeine, the relationship flips: poor metabolizers feel less effect because they can't activate the drug.

See all drugs affected by CYP2D6 →

Related medications

Find out how your genetics affect Nolvadex

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.